Blog

New formulation of Photosoft therapy shows increased effect in ovarian cancer

New in vitro data shows effectiveness of IVX-P02, an improved formulation of Photosoft™ Oral IVX-P02 is 15 times more effective than Photosoft™ Oral at killing ovarian cancer cells in vivo animal trials to be commenced this year, moving to human clinical trials in 2019 Melbourne, Australia, 25 September 2018: Cancer therapy developer Invion Limited (ASX:…
Read more

Photosoft granted patent protection in Australia

Invion’s licensed PhotosoftTM technology receives patent protection until 2033 PhotosoftTM targeted as a therapy for a range of cancers including ovarian, lung, skin and prostate cancer Melbourne, Australia, 10 September 2018: ASX-listed life sciences company Invion Limited (ASX:IVX) announces the grant in Australia of the patent for chlorin e4 sodium, a new generation photodynamic therapy…
Read more

Invion to spinout respiratory assets and advance clinical development in China

Invion to demerge respiratory assets into stand-alone company, Chronic Airway Therapeutics Limited (CAT) CAT to focus on development of respiratory assets in China, expediting advancement into Phase 3 clinical trials Eligible Invion shareholders will, on completion of the demerger, receive one share in Chronic Airway Therapeutics Limited for each Invion share they hold Melbourne, Australia…
Read more

Photosoft efficiently destroys ovarian cancer cells in vitro

Invion and Hudson Institute of Medical Research are collaborating on R&D projects for the PhotosoftTM technology as a treatment of a range of cancers PhotosoftTM characterisation studies have been completed in multiple ovarian cancer cell lines PhotosoftTM caused efficient and highly effective cancer cell destruction in vitro Melbourne, Australia, 5 July 2018: Invion Limited (ASX:…
Read more